作者: Gao, Qiang ; Bao, Linlin ; Mao, Haiyan ; Wang, Lin ; Xu, Kangwei ; Yang, Minnan ; Li, Yajing ; Zhu, Ling ; Wang, Nan ; Lv, Zhe ; Gao, Hong ; Ge, Xiaoqin ; Kan, Biao ; Hu, Yaling ; Liu, Jiangning ; Cai, Fang ; Jiang, Deyu ; Yin, Yanhui ; Qin, Chengfeng ; Li, Jing ; Gong, Xuejie ; Lou, Xiuyu ; Shi, Wen ; Wu, Dongdong ; Zhang, Hengming ; Zhu, Lang ; Deng, Wei ; Li, Yurong ; Lu, Jinxing ; Li, Changgui ; Wang, Xiangxi ; Yin, Weidong ; Zhang, Yanjun ; Qin, Chuan
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6μg per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, resp., without observable antibody-dependent enhancement of infection. These data support the clin. development and testing of PiCoVacc for use in humans.